IL2 and neoplasm: GHCer could be transferred from cancer cells into non-tumor cells located in the tumor microenvironment, such as endothelial cells, promoting angiogenesis, as well as into T cells, inhibiting IL-2, interferon-γ, and IL-4 secretion, promoting immunosuppression.